Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
JYNT vs ACHC vs ENSG vs HCA vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
JYNT vs ACHC vs ENSG vs HCA vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $124M | $2.32B | $10.02B | $97.29B | $16.68B |
| Revenue (TTM) | $57M | $3.37B | $5.27B | $75.60B | $21.45B |
| Net Income (TTM) | $3M | $-1.11B | $363M | $6.78B | $1.70B |
| Gross Margin | 81.4% | 56.2% | 15.2% | 41.5% | 42.8% |
| Operating Margin | 1.1% | 11.7% | 8.5% | 15.8% | 16.1% |
| Forward P/E | 45.0x | 16.7x | 22.7x | 14.4x | 10.7x |
| Total Debt | $2M | $2.65B | $4.15B | $50.20B | $13.17B |
| Cash & Equiv. | $24M | $133M | $504M | $1.04B | $2.88B |
JYNT vs ACHC vs ENSG vs HCA vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| The Joint Corp. (JYNT) | 100 | 57.5 | -42.5% |
| Acadia Healthcare C… (ACHC) | 100 | 88.0 | -12.0% |
| The Ensign Group, I… (ENSG) | 100 | 392.2 | +292.2% |
| HCA Healthcare, Inc. (HCA) | 100 | 407.1 | +307.1% |
| Tenet Healthcare Co… (THC) | 100 | 874.9 | +774.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JYNT vs ACHC vs ENSG vs HCA vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
JYNT lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, ACHC doesn't own a clear edge in any measured category.
ENSG ranks third and is worth considering specifically for growth exposure.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 18.7% revenue growth vs THC's 3.1%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.31, yield 0.7%
- Beta 0.31, yield 0.7%, current ratio 0.83x
- 9.0% margin vs ACHC's -32.8%
- Beta 0.31 vs JYNT's 0.94
THC is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 5.1% 10Y total return vs ENSG's 7.4%
- Lower volatility, beta 0.74, current ratio 1.76x
- PEG 0.32 vs ENSG's 1.64
- Lower P/E (10.7x vs 14.4x), PEG 0.32 vs 0.68
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs THC's 3.1% | |
| Value | Lower P/E (10.7x vs 14.4x), PEG 0.32 vs 0.68 | |
| Quality / Margins | 9.0% margin vs ACHC's -32.8% | |
| Stability / Safety | Beta 0.31 vs JYNT's 0.94 | |
| Dividends | 0.7% yield, 5-year raise streak, vs ENSG's 0.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.7% vs JYNT's -17.5% | |
| Efficiency (ROA) | 11.3% ROA vs ACHC's -18.6%, ROIC 19.9% vs 5.9% |
JYNT vs ACHC vs ENSG vs HCA vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JYNT vs ACHC vs ENSG vs HCA vs THC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 3 of 6 categories
JYNT leads 0 • ACHC leads 0 • ENSG leads 0 • HCA leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 1334.8x JYNT's $57M. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to ACHC's -32.8%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $57M | $3.4B | $5.3B | $75.6B | $21.5B |
| EBITDAEarnings before interest/tax | $2M | $588M | $558M | $15.5B | $4.3B |
| Net IncomeAfter-tax profit | $3M | -$1.1B | $363M | $6.8B | $1.7B |
| Free Cash FlowCash after capex | $3M | -$215M | $406M | $7.7B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +81.4% | +56.2% | +15.2% | +41.5% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +1.1% | +11.7% | +8.5% | +15.8% | +16.1% |
| Net MarginNet income ÷ Revenue | +5.7% | -32.8% | +6.9% | +9.0% | +7.9% |
| FCF MarginFCF ÷ Revenue | +4.7% | -6.4% | +7.7% | +10.2% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.3% | +7.6% | +18.4% | +6.7% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +71.4% | -49.8% | +21.9% | +44.6% | +87.6% |
Valuation Metrics
THC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, THC trades at a 73% valuation discount to JYNT's 45.7x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs ENSG's 2.13x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $124M | $2.3B | $10.0B | $97.3B | $16.7B |
| Enterprise ValueMkt cap + debt − cash | $103M | $4.8B | $13.7B | $146.5B | $27.0B |
| Trailing P/EPrice ÷ TTM EPS | 45.74x | -2.07x | 29.36x | 15.33x | 12.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 44.96x | 16.75x | 22.68x | 14.40x | 10.65x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.13x | 0.73x | 0.37x |
| EV / EBITDAEnterprise value multiple | 127.28x | 8.38x | 25.40x | 9.46x | 6.27x |
| Price / SalesMarket cap ÷ Revenue | 2.27x | 0.70x | 1.98x | 1.29x | 0.78x |
| Price / BookPrice ÷ Book value/share | 8.72x | 1.07x | 4.52x | — | 1.93x |
| Price / FCFMarket cap ÷ FCF | 371.84x | — | 27.02x | 12.65x | 6.59x |
Profitability & Efficiency
Evenly matched — JYNT and HCA each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
THC delivers a 19.6% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-41 for ACHC. JYNT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), JYNT scores 7/9 vs ENSG's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +16.9% | -40.9% | +16.6% | — | +19.6% |
| ROA (TTM)Return on assets | +5.0% | -18.6% | +6.8% | +11.3% | +5.7% |
| ROICReturn on invested capital | — | +5.9% | +7.0% | +19.9% | +13.2% |
| ROCEReturn on capital employed | -2.9% | +7.5% | +10.2% | +27.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 5 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.13x | 1.24x | 1.86x | — | 1.47x |
| Net DebtTotal debt minus cash | -$22M | $2.5B | $3.7B | $49.2B | $10.3B |
| Cash & Equiv.Liquid assets | $24M | $133M | $504M | $1.0B | $2.9B |
| Total DebtShort + long-term debt | $2M | $2.7B | $4.2B | $50.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | — | -5.99x | 88.33x | 5.37x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,325 today (with dividends reinvested), compared to $1,625 for JYNT. Over the past 12 months, THC leads with a +27.7% total return vs JYNT's -17.5%. The 3-year compound annual growth rate (CAGR) favors THC at 39.8% vs ACHC's -28.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.8% | +76.2% | -1.4% | -7.3% | -4.5% |
| 1-Year ReturnPast 12 months | -17.5% | +4.0% | +26.0% | +23.8% | +27.7% |
| 3-Year ReturnCumulative with dividends | -40.9% | -63.5% | +85.9% | +59.6% | +173.1% |
| 5-Year ReturnCumulative with dividends | -83.8% | -60.3% | +105.6% | +111.2% | +193.3% |
| 10-Year ReturnCumulative with dividends | +192.6% | -57.2% | +738.2% | +457.9% | +511.4% |
| CAGR (3Y)Annualised 3-year return | -16.1% | -28.5% | +23.0% | +16.9% | +39.8% |
Risk & Volatility
Evenly matched — ACHC and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than JYNT's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACHC currently trades 83.4% from its 52-week high vs JYNT's 64.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 0.82x | 0.38x | 0.31x | 0.74x |
| 52-Week HighHighest price in past year | $13.47 | $30.20 | $218.00 | $556.52 | $247.21 |
| 52-Week LowLowest price in past year | $7.50 | $11.43 | $134.68 | $330.00 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +64.5% | +83.4% | +78.6% | +78.2% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 45.7 | 42.7 | 22.0 | 30.7 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 59K | 3.1M | 364K | 1.0M | 1.2M |
Analyst Outlook
Evenly matched — ENSG and HCA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: JYNT as "Buy", ACHC as "Buy", ENSG as "Buy", HCA as "Buy", THC as "Buy". Consensus price targets imply 130.1% upside for JYNT (target: $20) vs 1.6% for ACHC (target: $26). For income investors, HCA offers the higher dividend yield at 0.68% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | $25.59 | $222.33 | $527.45 | $259.50 |
| # AnalystsCovering analysts | 8 | 25 | 13 | 46 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.1% | +0.7% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 12 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | — | $0.24 | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.1% | +2.2% | +0.2% | +10.3% | +8.6% |
THC leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 3 categories are tied.
JYNT vs ACHC vs ENSG vs HCA vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is JYNT or ACHC or ENSG or HCA or THC a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Tenet Healthcare Corporation (THC) offers the better valuation at 12. 3x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate The Joint Corp. (JYNT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — JYNT or ACHC or ENSG or HCA or THC?
On trailing P/E, Tenet Healthcare Corporation (THC) is the cheapest at 12.
3x versus The Joint Corp. at 45. 7x. On forward P/E, Tenet Healthcare Corporation is actually cheaper at 10. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus The Ensign Group, Inc. 's 1. 64x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — JYNT or ACHC or ENSG or HCA or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +193.
3%, compared to -83. 8% for The Joint Corp. (JYNT). Over 10 years, the gap is even starker: ENSG returned +738. 2% versus ACHC's -57. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — JYNT or ACHC or ENSG or HCA or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 31β versus The Joint Corp. 's 0. 94β — meaning JYNT is approximately 205% more volatile than HCA relative to the S&P 500. On balance sheet safety, The Joint Corp. (JYNT) carries a lower debt/equity ratio of 13% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — JYNT or ACHC or ENSG or HCA or THC?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: The Joint Corp. grew EPS 148. 7% year-over-year, compared to -537. 4% for Acadia Healthcare Company, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — JYNT or ACHC or ENSG or HCA or THC?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -1. 6% for JYNT. At the gross margin level — before operating expenses — THC leads at 82. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is JYNT or ACHC or ENSG or HCA or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus The Ensign Group, Inc. 's 1. 64x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Tenet Healthcare Corporation (THC) trades at 10. 7x forward P/E versus 45. 0x for The Joint Corp. — 34. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JYNT: 130. 1% to $20. 00.
08Which pays a better dividend — JYNT or ACHC or ENSG or HCA or THC?
In this comparison, HCA (0.
7% yield), ENSG (0. 1% yield) pay a dividend. JYNT, ACHC, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is JYNT or ACHC or ENSG or HCA or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31), 0. 7% yield, +457. 9% 10Y return). Both have compounded well over 10 years (HCA: +457. 9%, ACHC: -57. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between JYNT and ACHC and ENSG and HCA and THC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: JYNT is a small-cap quality compounder stock; ACHC is a small-cap quality compounder stock; ENSG is a mid-cap high-growth stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock. HCA pays a dividend while JYNT, ACHC, ENSG, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.